Ozgur Delikanli
Dr. Rajvinder Kaur Trautmann
Vered Katz Ben-Yair, MSc
Co-founder, Chief Executive Officer
Ozgur Delikanli is a New York-based entrepreneur, businessman and investor. He holds B.S. in Engineering and M.A. Economics degrees. Ozgur believes that future is in life sciences. He is using his business expertise to oversee Neuron D’s business and business development models. He is constantly searchi
Co-founder, Chief Executive Officer
Ozgur Delikanli is a New York-based entrepreneur, businessman and investor. He holds B.S. in Engineering and M.A. Economics degrees. Ozgur believes that future is in life sciences. He is using his business expertise to oversee Neuron D’s business and business development models. He is constantly searching and communicating with new markets and innovative approaches.
Vered Katz Ben-Yair, MSc
Dr. Rajvinder Kaur Trautmann
Vered Katz Ben-Yair, MSc
Chief Operating Officer
An operational leader with 15+ years of experience in pharma and biotech, specializing in oncology, GI and rare diseases. Drawing on her background in program management, clinical operations and asset project leadership, Vered leads Neuron D's operational strategy and business execution, building the foundation to bring Neuron D's 3D platform to market.
Dr. Rajvinder Kaur Trautmann
Dr. Rajvinder Kaur Trautmann
Dr. Rajvinder Kaur Trautmann
Senior R&D Associate, Neuroscience
Rajvinder Kaur is a neurobiologist, received her Ph.D. degree from the Faculty of Biology at the Technische Universität Darmstadt, Germany. Her cross-disciplinary research expertise includes pharmacological modulators and ionizing radiation, neuronal activity and plasticity, 2D and 3D mammalian cell cultu
Senior R&D Associate, Neuroscience
Rajvinder Kaur is a neurobiologist, received her Ph.D. degree from the Faculty of Biology at the Technische Universität Darmstadt, Germany. Her cross-disciplinary research expertise includes pharmacological modulators and ionizing radiation, neuronal activity and plasticity, 2D and 3D mammalian cell culture systems, stem cell differentiation, cell-based biochemical assays, array-based extracellular recordings, animal research, and imaging.
Prof. Dr. Caghan Kizil
Prof. Dr. Carsten Werner
Dr. Rajvinder Kaur Trautmann
Co-founder, Scientific Advisor, Neuroscience
Caghan Kizil is a Professor of Neurological Science at Columbia University Irving Medical Center, New York, USA., He was the founding CEO of Neuron D from 2019 to 2022.
Prof. Dr. Carsten Werner
Prof. Dr. Carsten Werner
Prof. Dr. Carsten Werner
Co-founder, Scientific Advisor, Material Sciences
Carsten Werner is a professor for Biofunctional Polymer Materials at the Technische Universität Dresden, Center for Regenerative Therapies Dresden and directs the Biomaterials program at the Leibniz Institute of Polymer Research Dresden/Max Bergmann Center of Biomaterials Dresden (Germany).
Co-founder, Scientific Advisor, Material Sciences
Carsten Werner is a professor for Biofunctional Polymer Materials at the Technische Universität Dresden, Center for Regenerative Therapies Dresden and directs the Biomaterials program at the Leibniz Institute of Polymer Research Dresden/Max Bergmann Center of Biomaterials Dresden (Germany). His research aims at recapitulating functionalities of living matter in engineered polymer materials and includes studies on electrosurface phenomena, hemocompatibility of biomaterials and cell-instructive materials platforms for regenerative therapies and tissue models.
Dr. Uwe Freudenberg
Prof. Dr. Carsten Werner
Prof. Dr. Carsten Werner
Co-founder, Scientific Advisor
Uwe Freudenberg is a group leader for Matrix Engineering at the Institute of Biofunctional Polymer Materials at the Leibniz Institute of Polymer Research Dresden, Germany (IPF). He received his doctoral degree (Dr.-Ing.) from the Faculty of Mechanical Science and Engineering at the Technische Universität Dres
Co-founder, Scientific Advisor
Uwe Freudenberg is a group leader for Matrix Engineering at the Institute of Biofunctional Polymer Materials at the Leibniz Institute of Polymer Research Dresden, Germany (IPF). He received his doctoral degree (Dr.-Ing.) from the Faculty of Mechanical Science and Engineering at the Technische Universität Dresden in 2007. His current research focuses on the development of multifunctional polymer materials for biomedical applications with special emphasis on GAG-based hydrogels.
...
Dr. Nicholas Dennison
Dr. Nambirajan Govindarajan
Dr. Nambirajan Govindarajan
R&D Associate, Engineering
Nicholas Dennison is a researcher at the Faculty of Chemistry, Technische Universität Dresden and Institute of Biofunctional Polymer Materials at the Leibniz Institute of Polymer Research Dresden, Germany (IPF). His expertise includes high-throughput screening automation for biological assays, high-content imag
R&D Associate, Engineering
Nicholas Dennison is a researcher at the Faculty of Chemistry, Technische Universität Dresden and Institute of Biofunctional Polymer Materials at the Leibniz Institute of Polymer Research Dresden, Germany (IPF). His expertise includes high-throughput screening automation for biological assays, high-content imaging and analysis, Design-of-experiment tools (DOE), hydrogel design for 3D cell cultures and compound screenings on in vitro tissue models.
Dr. Nambirajan Govindarajan
Dr. Nambirajan Govindarajan
Dr. Nambirajan Govindarajan
Strategic Advisor
Dr. N. Govindarajan works as Research and Innovation Manager at the German Cancer Research Center (DKFZ) in Heidelberg, Germany, bridging the fields of Artificial Intelligence and Life Sciences. Govind brings to our team his decade-long research experience in neurodegeneration along with many years of work experience in
Strategic Advisor
Dr. N. Govindarajan works as Research and Innovation Manager at the German Cancer Research Center (DKFZ) in Heidelberg, Germany, bridging the fields of Artificial Intelligence and Life Sciences. Govind brings to our team his decade-long research experience in neurodegeneration along with many years of work experience in grants consultancy, R&D, and business strategies to ensure our lasting impact on the drug development technology landscape.
Glioblastoma Avatar Personalized Medicine Platform Launched
We are excited to announce that we launched our 3D Glioblastoma platform "Glioblastoma Avatar" that will enable rapid personalized drug testing for GBM patients.